Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2020-01-29 Regulatory Filings
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-01-29 English
NYSE AMERICAN CERTIFICATION
Regulatory Filings
2020-01-28 English
FORM 8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A12B filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registrant, the securities to be registered, and a signature page. There are no financial statements, earnings data, or management discussion. The document is a regulatory filing related to securities registration, not a financial report or announcement of voting results, dividends, or management changes. Therefore, it fits best under Regulatory Filings (RNS). The document length is 3509 characters, which is relatively short and consistent with a regulatory filing form rather than a full report.
2020-01-28 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 for Annovis Bio, Inc. It is an acceleration request to have the registration statement declared effective earlier. The content is related to the process of securities registration and underwriting compliance, not a financial report or earnings release. The document length is short (2013 characters) and it is a formal communication about the timing of a filing becoming effective, not the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-01-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from Annovis Bio, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Registration Statement filing and acknowledges regulatory responsibilities. The document is short (2393 characters) and is a formal communication related to a regulatory filing process, not the filing itself or a financial report. It does not contain financial data or detailed report content but is an official regulatory correspondence. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and correspondence with the SEC.
2020-01-24 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 6 to a Form S-1 Registration Statement filed with the SEC. Form S-1 is used for registering securities for public offering under the Securities Act of 1933. The text includes details about registration fees, indemnification of directors and officers, and legal disclaimers related to the offering. There is no financial performance data, earnings information, or management discussion of results. The document is clearly a regulatory filing related to securities registration and offering, not a financial report, earnings release, or other report types. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial and contains detailed regulatory information, supporting a high confidence in this classification.
2020-01-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.